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ABSTRACT 
The αvβ6 integrin receptor has been shown to be overexpressed on many types of cancer 
cells, resulting in a more pro-invasive and aggressive phenotype, this makes it an attractive 
target for selective drug delivery. In tumours that over-express the αvβ6 receptor, cellular 
uptake of liposomes can be enhanced using ligand-targeted liposomes. It has previously been 
shown in both in vitro and in vivo studies that liposomal alendronate (L-ALD) can sensitise 
cancer cells to destruction by Vγ9Vδ2 T cells. It is hypothesised that by using the αvβ6-
specific peptide A20FMDV2 as a targeting moiety for L-ALD, the therapeutic efficacy of this 
therapy can be increased in αvβ6 positive tumours. Targeted liposomes (t-L) were formulated 
and the targeting efficacy of targeted liposomes (t-L) was assessed by cell uptake and 
cytotoxicity studies in the αvβ6 positive cells line A375Pβ6. Bio-distribution of both L and t-
L were carried out in αvβ6 positive (A375Pβ6 and PANC0403) and αvβ6 negative 
(A375Ppuro and PANC-1) subcutaneous tumour mouse models. Immuno-compromised mice 
bearing A375Pβ6 experimental metastatic lung tumours were treated with L-ALD or t-L-
ALD as monotherapies or in combination with ex vivo-expanded  Vγ9Vδ2 T cells. In vitro, 
αvβ6-dependant uptake of t-L was observed, with t-L-ALD being more effective than L-ALD 
at sensitising A375Pβ6 to γδ T cells. Interestingly, t-L-ALD led to slightly higher but not 
significant reduction in tumour growth compared to L-ALD, when used as monotherapy in 
vivo. Moreover, both L-ALD and t-L-ALD led to significant reductions in tumour growth 
when used in combination with γδ T cells in vivo but t-L-ALD offered no added advantage 
compared to L-ALD.  
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INTRODUCTION 
Integrins are heterodimeric glycoproteins composed of non-covalently linked α and β 
subunits and are involved in a variety of cell processes including proliferation [1], survival 
[2], migration [3] and invasion [4], giving them a key role in cancer. The αvβ6 integrin 
receptor is expressed on epithelia, usually only in the process of tissue remodelling [5] and 
wound healing [6]. However, overexpression of this receptor has been detected in many types 
of tumours including colon cancer [7], gastric carcinomas [8], oral squamous cell carcinomas 
[9] and breast cancer and is typically associated with a more pro-invasive and aggressive 
phenotype [10, 11]. Therefore, this integrin provides an attractive molecular target for 
targeted drug delivery to cancer cells. The 20 amino acid peptide, A20FMDV2, 
(NAVPNLRGDLQVLAQKVART), derived from the VP1 coat-protein of the foot-and-
mouth disease virus, has shown very good specificity for αvβ6 [12]. This peptide has been 
shown to effectively and specifically target αvβ6-expressing cancers [13]. A20FMDV2 has 
not previously been conjugated to any type of nanocarrier and its ability to target 
nanoformulations has not been tested. Only one other study has targeted the αvβ6 integrin 
receptor using a nanoparticle formulation. In that study, liposomes were targeted using an 
alternative peptide, H2009.1 [14]. 
 
Alendronate (ALD), is a nitrogen containing bisphosphonate (N-BP) that can sensitise 
tumour cells to killing by Vγ9Vδ2 T cells in both in vitro [15-19] and in vivo studies[20-27]. 
The encapsulation of ALD in liposomes (L-ALD), has been shown to increase its therapeutic 
efficacy [24]. Long-circulating liposomes passively target the tumour due to the enhanced 
permeation and retention (EPR) effect[28], leading to a greater amount of the encapsulated 
drug reaching the tumour cells.  
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The aim of this study is to formulate αvβ6 integrin targeted ALD liposomes (t-L-ALD), using 
the peptide A20FMDV2. It is hypothesised that A20FMDV2 conjugation to liposomal 
alendronate will promote αvβ6-receptor mediated endocytosis and improved therapeutic 
efficacy in combination with γδ T cell immunotherapy in vitro and possibly in vivo. 
 
MATERIALS AND METHODS 
 
Additional methods are described in supplementary information. 
 
Materials 
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and 1,2-dipalmitoyl 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt) 
(DSPE-PEG2000) were obtained from Lipoid (Germany). 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine-N-(carboxyfluorescein) (CF-DOPE), 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-diethylenetriaminepentaacetic acid (ammonium salt) (DSPE-DTPA) 
and DSPE-PEG(2000) maleimide were purchased from Avanti Polar Lipids, Inc (USA). The 
cysteine-modified A20FMDV2 peptide (Sequence: NAVPNLRGDLQVLAQKVART-
Cysteine, Purity: >95%) was purchased from Genscript Limited (Hong Kong). Dextrose, 
cholesterol, sodium chloride, phosphate buffered saline (PBS) tablets, N-(2-
Hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid) (HEPES), methanol (Analytical reagent 
grade), chloroform (Analytical reagent grade), and Sepharose 2B were purchased from Sigma 
(UK). LavaPep™ Protein and Peptide quantification kit was obtained from Web Scientific 
(UK). PD-10 desalting column was obtained from GE Healthcare Life Sciences (UK). Snake 
Skin® dialysis tubing (MWCO 10000 Da) was purchased from Thermo-fisher (USA). 
Dulbecco’s modified Eagle’s medium (DMEM), Roswell Park Memorial Institute medium 
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(RPMI), Glutamax™ and antibiotic-antimycotic solution were purchased from Invitrogen 
(UK). Foetal Bovine Serum was purchased from First Link (UK). Human AB serum (male) 
was obtained from Sigma (UK). Thiazolyl blue tetrazolium bromide (MTT), tropolone and 
alendronate sodium trihydrate were obtained from Alfa Aesar (UK). DMSO was obtained 
from Fisher (UK). Human IFN-γ ELISA Ready-set-go kit was purchased from eBiosciences 
(UK). The 10D5 antibody was obtained from Abcam (UK). FITC labelled secondary 
antibody was purchased from Cell Signalling (UK). D-Luciferin was obtained from Perkin 
Elmer (UK). Indium-111 chloride was obtained from Mallinckrodt (NL). Thin layer 
chromatography (TLC) strips for radio-labelling were purchased from Agilent Technologies 
UK Ltd (UK). Isoflurane (IsoFlo®) for anaesthesia was purchased from Abbott Laboratories 
Ltd (UK). All reagents were used without further purification. 
 
Preparation of liposomes 
Stock solutions of 40 mg/ml were prepared in chloroform/methanol (4:1 v/v). To avoid 
degradation, lipid solutions were stored at -20°C under nitrogen.  Untargeted Liposomes (L) 
were prepared by thin film hydration (TFH). DSPC, cholesterol and DSPE-PEG2000 
(55:40:5 molar ratio) were added to a 25 ml round-bottom flask and 2 ml 
chloroform/methanol (4:1 v/v) was added. A thin lipid film was formed upon removal of the 
solvent under reduced pressure using a rotary evaporator (Rotavapor® R-210, Buchi UK). 
The lipid film was flushed with nitrogen to remove any remaining traces of organic solvent. 
The film was then hydrated by adding 1 ml of PBS, adjusted to pH 7.4. The liposome 
suspension was left for 1 h at 60°C and was vortexed (Vortex genie 2, Scientific Industries 
Inc, USA) every 15 min [29]. Liposomes were prepared at a final concentration of 25 mM 
total lipid. The size and polydispersity (PDI) of the liposomes was reduced with serial 
extrusion using the mini-extruder (Avanti Polar Lipids, USA) through polycarbonate 
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membranes (Avanti Polar Lipids, USA) with pore sizes 0.8 µm (5x), 0.2 µm (5x), 0.1 µm 
(10x) and 0.08 µm (15x) at 60°C. The resulting suspension was stored at 4°C. 
 
For targeted liposomes (t-L), the liposomes were formed as above with the addition of 0.5 - 2 
%mol of DSPE-PEG2000-maleimide. The overall formulation of the liposomes was 
DSPC:cholesterol:DSPE-PEG2000:DSPE-PEG2000-maleimide (55:40:3-4.5:0.5-2 molar ratio). 
The DSPE-PEG2000 was reduced in order to keep the overall percentage of PEG2000 at 5 
%mol. After the liposomes were formed, they were flushed with nitrogen and incubated with 
A20FMDV2 peptide at RT overnight (25-100 μg peptide/μmol lipid) under nitrogen. Excess 
peptide and ALD was removed by eluting the liposomes through a Sephadex 2B column with 
PBS; or via overnight dialysis against PBS using a dialysis bag with a MWCO of 10,000 kD 
at room temperature.   
 
For cellular uptake studies, fluorescent liposomes were formed as above but with the 
inclusion of 1% mol CF-DOPE to give a final liposome composition of DSPC:CF-
DOPE:cholesterol:DSPE-PEG2000:DSPE-PEG2000-maleimide (54:1:40:4:1 molar ratio).  
 
Liposomes containing alendronate (L-ALD and t-L-ALD) were prepared as above, but the 
lipid film was hydrated with 1 ml of 100 mM solution of ALD in HEPES Buffered Saline 
(HBS, 20mM HEPES, 150 mM NaCl). Un-encapsulated ALD was removed by overnight 
dialysis against HBS using a dialysis bag with a MWCO of 10,000 kD. 
 
Peptide quantification 
The amount of peptide conjugated to the liposomes was determined by LavaPep™ Protein 
and Peptide quantification kit. A calibration curve was obtained in the range 0.122–500 
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μg/ml using free A20FMDV2. Liposomes were diluted 100 times in deionised water and the 
amount of peptide quantified according to the manufacturer’s instructions. Briefly, 50 μl of 
the diluted sample was incubated with 50 μl of LavaPep working solution for 60 minutes in 
the dark at RT. The fluorescence intensity was then measured using 540±10 nm and 630±10 
nm excitation and emission filters, respectively (FLUOStar Omega, BMG Lab Tech). The per 
cent peptide conjugated to the liposomes was calculated by quantifying the amount of peptide 
in the liposome sample before and after purification.  
 
Cell culture conditions 
The cell lines PANC-1 (CRL-1469™, pancreatic), PANC0403 (CRL-2555™, pancreatic) and 
4T1 (CRL-2539™, breast) were obtained from ATCC®. A375Ppuro and A375Pβ6puro cell 
lines were created using the human melanoma cell line A375P (CRL-3224™, melanoma), 
which was infected with pBabe retroviruses encoding puromycin resistance alone or in 
combination with cDNA for human β6, as previously reported[12]. The A375Ppuro and 
A375Pβ6 cell lines were a kind gift from Prof. John Marshall (QMUL). The A375Pβ6 cell 
line was subsequently transfected with firefly luciferase (luc) using an SFG retroviral vector 
whereby luc was co-expressed with dsTomato red fluorescent protein. Transduced cells were 
then flow sorted for red fluorescence to obtain a pure A375Pβ6-luc cell line[24]. All cell lines 
were maintained at 37° , 5% CO2 and 5% relative humidity. Advanced RPMI (PANC-1, 
PANC0403, 4T1) or DMEM media (A375Ppuro, A375Pβ6puro) were used, both of these 
were supplemented with 10% FBS, 1% GlutaMAX™ and 1% Penicillin/Streptomycin. 
 
Characterisation of cell lines for αvβ6 integrin expression 
αvβ6 integrin receptor expression was confirmed by 10D5 antibody staining and flow 
cytometry. Cells (1 x 105/100 µl) were incubated with 5 μl of 10D5 or the isotype control 
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(IgG FITC) for 30 minutes at 4°C, washed twice with 1 ml PBS before 30 min incubation 
with 2.5 μl of the FITC labelled IgG secondary antibody at 4°C then washed with PBS. Using 
the FL1 detector, 10,000 cells were gated and the fluorescence was analysed under live 
gating. The cells were read on a BD FACS Calibur™  flow cytometer obtained from BD 
Bioscience (US) and analysed using FlowJo software. 
 
Cellular uptake of liposomes using flow cytometry 
Cells were plated in a 24 well plate at a density of 50,000 cells/well and left overnight to 
allow the cells to attach. Cells were treated with 32.5 – 130 μM CF-DOPE containing 
liposomes (L or t-L) in complete media (10% FBS) for 1 or 4 h. In order to determine if the 
increased uptake of t-L was αvβ6 receptor specific, peptide inhibition studies were carried 
out. Cells were incubated at 4°C for 10 minutes and were then treated with 0.2 ml of 50 
μg/ml free peptide in complete media for a further 10 min on ice. The fluorescently labelled L 
and t-L (32.5 – 130 μM) were then additionally incubated with the cells for 1 or 4 h. 
Additional peptide (50 μg in 25 μl PBS) was added after 1 h to ensure that the αvβ6 receptors 
remained blocked. Upon completion of the incubation period, the cells were washed with 
PBS, trypsinised and transferred into BD flow cytometer tubes. The cells were washed in 
PBS and re-suspended in 500 µL of PBS. The fluorescence was analysed in triplicates for 
each condition using the FL1 detector with 10,000 cells gated. All flow cytometry data was 
acquired using a BD FACS Calibur™  flow cytometer obtained from BD Bioscience (US) and 
analysed using FlowJo software. 
 
Treatment of cancer cell lines with L-ALD/t-L-ALD and γδ T cells in combination 
therapy studies 
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The cell lines A375Ppuro, A375Pβ6, PANC-1 and PANC0403 were seeded at 50,000 
cells/well in 96 well plates. Cells were treated for 24 h with 30 or 60 μM of ALD, L-ALD or 
t-L-ALD. Empty-liposomes (EL) and targeted EL (t-EL) were used as controls at lipid 
concentrations equivalent to that of the L-ALD and t-L-ALD, depending on the drug loading. 
The treatments were removed and replaced with 2.5 x 105 ex vivo expanded Vγ9Vδ2 T cells, 
or γδ T cell culture media as a control, for a further 24 h. The γδ T cells were then removed 
and the cell monolayers were washed with PBS before cell viability was assessed with MTT 
as described below. 
 
MTT assay 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) solution was prepared 
in PBS at a concentration of 5 mg/ml and was diluted in media (1:6) prior to use. The 
supernatant of each well was removed and MTT solution (120 µl) was added to each well. 
The plates were then incubated at 37°C and 5% relative humidity for 3 h. The MTT solution 
from each well was removed and DMSO (200 µl/well for 96 well) was added and incubated 
for 5 min at 37°C, to eliminate air bubbles. The absorbance was read at 570 nm with 
reference at 630 nm (FLUOStar Omega, BMG Lab Tech). Percentage cell survival was 
determined by calculating the absorbance of treated cells as a percentage of that of untreated 
cells 
 
 
Determination of IFN-γ concentration by ELISA 
Supernatant from the co-culture assay was removed from each of the wells immediately 
before the cytotoxicity assay was performed. The supernatant was centrifuged to remove the 
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γδ T cells and was stored at -80°C until required. Supernatants were diluted 1:40 and 
analysed using a human IFN-γ ELISA Ready-set-go-kit as per the manufacturer’s protocol.  
 
Radiolabelling of DTPA containing liposomes  
DTPA containing liposomes were prepared with the TFH method as above but with 1% of 
the DSPC replaced with 1% molar ratio of DSPE-DTPA, and radiolabelled with 111In [30]. 
The required volume of 111In, containing 1 MBq per mouse for bio-distribution studies or 10-
15 MBq per mouse for imaging studies was added to 2 M ammonium acetate buffer (one-
ninth of the reaction volume, pH 5.5). This was then added to the liposome sample (100 μl of 
20 mM liposomes/mouse) to give a final ammonium acetate concentration of 0.2 M, and 
incubated for 30 min at RT. The reaction was quenched by the addition of 0.1M EDTA 
solution to the mixture (5% v/v of the reaction mixture) to chelate free 111In. Unbound 
111In:EDTA was removed using NAP-5 desalting columns equilibrated with PBS and the 
liposomes were collected in fraction 1-3 (~150 μl per injection dose).  
 
Efficiency and stability of the radiolabelling in serum 
Samples of the radiolabelled liposomes or 111In:EDTA were spotted in glass microfibre 
chromatography paper impregnated with silica gel. These strips were then developed using a 
mobile phase of 50 mM EDTA in 0.1 M ammonium acetate. Strips were placed on a multi-
purpose storage phosphor screen (Cyclone®, Packard, Japan) and kept in an autoradiography 
cassette (Kodak Biomax Cassette®) for 10 min. Quantitative autoradiography counting was 
then carried out using a cyclone phosphor detector (Packard®, Australia). The labelling 
stability was tested by incubation of the radio-conjugates in the presence or absence of FBS. 
Samples were diluted in 50% FBS or PBS [1:2 (v/v)], and incubated for 24 h at 37°C. The 
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percentage of 111In:EDTA (immobile spot) remained conjugated to the liposomes was 
evaluated by TLC, using the same protocol as described above. 
 
Animal Models 
All animal experiments were performed in compliance with the UK Home Office (1989) 
Code of Practice for the housing and care of Animals used in Scientific Procedures. Female 
SCID/Beige (SPECT/CT studies) and male NOD SCID gamma (NSG) mice (bio-distribution 
and therapy studies), 4-6 weeks old, were obtained from Charles River (UK). Female 
BALB/c mice, 4-6 weeks old, were obtained from Harlan Laboratories (UK). For the human 
xenograft tumour models, subcutaneous (s.c.) tumours were established by injecting 5 x 106 
cells in 100 μl PBS into each of the rear-flanks of SCID/Beige. For the murine tumour model, 
1 x 106 cells in 100 μl PBS were injected into each of the rear flanks of BALB/c mice. The 
size of the tumour was measured using callipers and tumour volume were determined using 
the equation:  
Tumour Volume (mm3) = (A2Bπ)/6 
where A and B represent the width and the length of the tumours, respectively [31]. 
Experiments commenced when tumours reached ~300 mm3. For the lung model, 5 x 105 cells 
were injected into the tail vein of NSG mice. This tumour model was monitored via s.c. 
injection of the mice with 100 µl 30 mg/ml luciferin /20 g mouse and subsequent scanning 
after 20 min using an IVIS Lumina series III In Vivo Imaging system (Perkin-Elmer). Images 
were quantitatively analysed by drawing regions of interest (ROI) around the tissues using 
Living Image 4.3.1 Service Pack 2 software (Perkin-Elmer, USA). 
 
 
Whole body SPECT/CT imaging of radiolabelled liposomes in tumour-bearing mice 
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Mice were injected with liposomes containing 2 μmol lipid and radiolabelled with 1 MBq or 
10-15 MBq, for bio-distribution and SPECT/CT studies, respectively, via tail vein injection. 
Mice were imaged with nanoSPECT/CT scanner (Bioscan ®, USA) 0-30 min, 4 h and 24 h 
post i.v. injection. For each mouse, a tomography was initially performed (45 Kvp; 1000 ms) 
to obtain parameters required for the SPECT and CT scanner, including the starting line, 
finish line and axis of rotation of the acquisition for each mouse. SPECT scans were obtained 
using a 4-head scanner with 1.4 mm pinhole collimators and the following settings: number 
of projections: 24; time per projection: 60 sec and duration of the scan 60 min. CT scans were 
obtained at the end of each SPECT acquisition using 45Kvp. All data were reconstructed with 
MEDISO (medical Imaging System) and the combining of the SPECT and CT acquisitions 
were performed using PMOD® software. 
 
Gamma counting of radiolabelled liposomes in tumour-bearing mice 
After 24 h, the mice were perfused with ~ 25 ml of 1000 U/L heparin in 0.9% sodium 
chloride in order to remove any liposomes remaining in the blood. The major organs (brain, 
lung, liver, spleen, kidney, heart, stomach and intestine), muscle, skin, bone (femur), carcass 
and tumours were collected, weighed and placed in scintillation vials. Additionally, 5 μl 
blood samples taken at various time points (5, 10, 30, 60, 240 and 1440 min), and urine and 
faeces collected with the aid of metabolic cages were also placed in scintillation vials for 
analysis. Each sample was analysed for [111In] specific activity using an automated gamma 
counter (LKB Wallac 1282 Compugamma, PerkinElmer, UK) together with dilutions of 
injected dose with dead time limit below 60%. The gamma rays emitted by the radioisotope 
were detected, quantified and corrected for physical radioisotope decay by the gamma 
counter. Radioactivity readings (counts per minute - CPM) were plotted as percentage of 
injected dose per organ or percentage of injected dose per gram of tissue.  
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Therapy study 
Male NSG mice (4-6 weeks) were inoculated with 5 x 106 A375Pβ6.luc cells by i.v injection 
to form experimental metastatic lung tumours. Bioluminescence imaging of mice was carried 
out on day 6 as described above and mice were divided into 4 treatment groups: naïve, L-
ALD, γδ T cells and L-ALD and γδ T cells combination treatment. Doses used in therapy 
experiments were 0.5 µmol of ALD/mouse (L-ALD) and 1 x 107 cells/mouse (γδ T cells), all 
injected via the tail vein. Three doses of each treatment were given at one-week intervals on 
dates 7, 14 and 21. In the case of the combination treatment, mice were pre-injected with L-
ALD (days 6, 13, and 20) then injected with γδ T cells (days 7, 14, and 21).  Tumour growth 
was monitored by bioluminescence imaging twice weekly, as described above.  
 
Determination of IFN-γ concentration with ELISA 
Animals from the therapy study were sacrificed and sera was analysed for human IFN-γ. Sera 
were diluted 1:2 and analysed using a human IFN-γ ELISA Ready-set-go-kit as per the 
manufacturer’s protocol.  
 
Pre-incubation of liposomes with mouse sera 
Mouse serum was obtained by allowing blood obtained from a terminal bleed of SCID/Beige 
mice to clot. The blood was centrifuged to pellet the clotted cells, and the serum was removed 
for further use. t-L were incubated with the mouse serum for various periods of time (10 
minutes, 1 hour, 4 hours) at 37°C. Any proteins that had not interacted with the surface of the 
liposomes were removed using a 10 cm Sepharose 2B column and eluted using PBS.  t-L 
were incubated with cells without any further processing and their uptake analysed by flow 
cytometry as described above.  
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Statistics 
For all experiments, data were presented as mean ± SD, except for therapy experiments 
where data were presented as mean ± SEM; n denotes the number of repeats. Independent 
variable Student t tests were performed using IBM SPSS version 20 for in vitro cytotoxicity 
studies. For in vivo studies, significant differences were examined using one-way ANOVA. 
The t-value, degrees of freedom and two-tailed significance (p-value) were determined. * p< 
0.05, ** p< 0.01 and *** p< 0.001 
 
RESULTS  
Preparation and characterisation of αvβ6 integrin-targeted liposomes (t-L) 
DSPC:Chol:DSPE-PEG2000 liposomes were prepared using lipid film hydration method and 
extrusion. t-L were prepared by incorporating DSPE-PEG2000-maleimide (0.5-2mol%) in the 
liposomes, then linked directly to αvβ6-targeting peptide. Free peptide was removed before 
further characterisation. The effects of %mol DSPE-PEG2000-maleimide and the peptide 
A20FMDV2 (25 μg/μmol lipid) on the physicochemical characteristics of the liposomes were 
examined. There was no significant difference in the hydrodynamic size (157.8 – 159.1 nm), 
PDI (0.080-0.098) or zeta potential (-12.5 to -14.6 mV) of the liposomes when DSPE-
PEG2000-maleimide (1 mol %) or A20FMDV2 were included in the formulation (Table 1). 
The size of the liposomes is in the range reported to be extravasated in regions of leaky 
vasculature as part of the EPR effect [32]. The low PDI values indicated that the liposomes 
were homogenous in size and the absence of liposome aggregation. The identical 
physicochemical characteristics of the L and t-L ensure that any differences in behaviour of 
these liposomes are solely due to the ability of the A20FMDV2 peptide to bind to the αvβ6 
integrin receptor. Liposomes containing 0.5 or 2 % DSPE-PEG2000-maleimide with or 
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without A20FMDV2 were also characterised and no significant change to the 
physicochemical characteristics of the liposomes were observed (Table S1). 
  
Initial peptide added 
(µg/µmol lipid)
[a] Size (nm) 
[b], [d] PDI[b], [d] Zeta Potential (mV) [c], [d] 
0 159.1 ± 1.7 0.098 ± 0.025 -14.6 ± 1.53 
25 157.8 ± 2.5 0.08 ± 0.013 -12.5 ± 1.08 
 
 
 
Optimisation of peptide loading on liposomes surface 
The effect of different initial addition of peptide on the final peptide loading on the t-L was 
examined. The LavaPep peptide assay was used to quantify the amount of peptide conjugated 
to the t-L and confirmed the purification of the t-L from the unconjugated A20FMDV2 using 
a Sepharose 2B column (Figure S1). In the case of 1 %mol DSPE-PEG2000-maleimide, the 
amount of A20FMDV2 added to the liposomes was adjusted from 25-100 μg per μmol lipid 
(10 – 40 nmol per mol lipid) (Table 2). Final peptide loading achieved ranged from 17.7 – 
21.7 μg peptide/ μmol lipid. There was no significant difference between the amount of 
A20FMDV2 added and the final peptide loading so it was therefore decided to use 25 μg 
peptide per μmol lipid (initial peptide loading) to prepare the t-L for subsequent studies. 
Additionally, when the %mol DSPE-PEG2000-maleimide was adjusted (0.5 or 2 mol %), the 
amount of peptide loaded onto the liposomes increased proportionally to the % of DSPE-
PEG2000-maleimide included in the liposome formulation (Table S2). All t-L used for in vitro 
and in vivo experiments contained 1 % mol DSPE-PEG2000-maleimide, as initial experiments 
determined that no improvement in targeting efficacy was observed when the DSPE-PEG2000-
maleimide content was increase to 2 % mol (Figures S2 and S3). 
 
 
Table 1: Physicochemical characteristics of liposomes with or without peptide. 
[a]  Liposomes containing 1 % mol DSPE-PEG
2000
-maleimide  
[b] Hydrodynamic diameter measured by dynamic light scattering. 
[c] Analysed by electrophoretic light scattering using 10mM NaCl. 
[d] Data are represented as mean ± SD. 
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Initial peptide 
added 
(µg/µmol lipid)  
Final peptide loading 
(µg/µmol lipid) [b] , 
[d]  
 nmol 
peptide/µmol lipid 
[b] , [d]  
% Peptide conjugated 
[c],  [d]   
25 21.7 ± 4.5 8.5 ± 1.8 84.8 ± 17.6 
50 17.7 ± 4.6 6.9 ± 1.8 34.5 ± 8.9 
100 21.2 ± 0.9 8.3 ± 0.4 20.67 ± 0.9 
 
 
 
 
In vitro targeting of t-L is αvβ6 integrin expression dependant 
The targeting efficacy of the liposomes was examined by looking at the uptake of 
fluorescently-labelled L and t-L in αvβ6 positive (A375Pβ6, 4T1 and PANC0403) and 
negative (A375Ppuro and PANC-1) cell lines. The results are displayed as mean fluorescence 
intensity (MFI) ratio of t-L to L. When a value of 1 is obtained the uptake of L and t-L were 
the same. A value of greater than 1 indicates that the t-L was taken up in greater quantities 
than L, and that a positive targeting effect has occurred. All experiments were carried out in 
media containing 10 % foetal bovine serum (FBS), as the large increase in internalisation of 
both L and t-L by starved cells in serum-free media masked any targeting effect of t-L 
(Figure S4) 
 
To evaluate the targeting efficiency of t-L, three αvβ6 integrin positive cell lines were used. 
These were the αvβ6 integrin-transfected human melanoma cell line A375Pβ6 and two cell 
lines that naturally express αvβ6: the human pancreatic cancer cell line, PANC0403 and the 
Table 2: Optimisation of peptide loading on liposomes. 
[a]  Liposomes containing 1 % mol DSPE-PEG
2000
-maleimide  
[b] Determined by LavaPep Peptide Quantification Kit. 
[c] Calculated as a percentage of initial peptide added. 
[d] Data are represented as mean  ± SD. 
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murine breast cancer cell line 4T1. The antibody 10D5 was used to measure the expression of 
αvβ6 integrin receptor on the panel of cancer cell lines used. As seen in Figure 1, 4T1 cells 
expressed the lowest amount of αvβ6 integrin receptor, while higher expression was seen in 
PANC0403 and A375Pβ6 cells. A correlation between the extent of αvβ6 integrin receptor 
expression on the surface of cells and the fold increase of t-L uptake compared to L could be 
seen. A375Pβ6 and PANC0403 showed a significantly higher fold increase of t-L/L 
compared to 4T1 (p < 0.01) at both 1 and 4 h. Additionally, at 4 h, A375Pβ6 demonstrated 
enhanced uptake of t-L/L compared to PANC0403 (p < 0.05). These data demonstrate the 
αvβ6 integrin-specific targeting effect of the liposomes. The results also suggest that a certain 
level of expression of the receptor is required for targeting to occur. 
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Figure 1: The effect of the extent of expression of αvβ6 integrin receptor on the uptake of t-L. 
(A) Representative images of cell lines incubated with the antibody 10D5 (specific to αvβ6) or an 
isotype control. Cells were analysed for αvβ6 integrin receptor expression using flow cytometry and 
FL-1 detector. In a comparison of the αvβ6 expression of different cell lines using the % positive cells 
gated in M1 or the MFI, the 4T1 cancer cell line showed the lowest receptor expression, while 
A375Pβ6 has the highest expression both in terms of % of positive cells and the number of receptors 
per cell. (B) Comparison of the MFI fold increase of fluorescently labelled t-L to L. Cells were treated 
with 32.5 µM L or t-L for 1 or 4 h. With increasing expression of αvβ6, the uptake of t-L in relation 
to L further increases. This is a further indication of the specificity of the t-L to the αvβ6 integrin 
receptor. Values are expressed as mean ± SD (n= 3). *P < 0.05, **P < 0.01 (ANOVA).  
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Uptake of t-L in αvβ6 expressing cells is inhibited with the free peptide A20FMDV2 
To further prove that enhanced liposomal targeting efficiency was related to the interaction 
between the peptide in t-L and the αvβ6 integrin receptor, peptide inhibition studies were 
carried out in the presence of excess A20FMDV2. Figure 2 displays the results obtained 
from the melanoma and pancreatic cancer paired cell lines. A 1.5- to 2-fold increase in the 
uptake of t-L compared to L was seen at both 1 and 4 h for the αvβ6 positive cell line, 
A375Pβ6 (Figure 2B).  However, enhancement of liposomal uptake was significantly 
reduced in the presence of the free A20FMDV2 (p < 0.05) with a ratio of ~1 obtained when 
compared with untargeted liposomes. A similar trend was observed for the αvβ6 positive 
PANC0403 cell line, whereby, when the cells were incubated with A20FMDV2, a lowering 
of the fold increase in liposomal uptake could be seen (p < 0.05) (Figure 2C). This further 
indicates that the increased amount of t-L taken up by the cells in relation to L is αvβ6 
receptor-dependent. The αvβ6 negative cell lines, A375Ppuro and PANC-1, (Figure S5) were 
also used to further confirm the specificity of the t-L. PANC-1 took up equal amounts of L 
and t-L and this did not change in the presence of free A20FMDV2. For A375Ppuro, a small 
increase in the amount of t-L when compared to L was observed in some conditions and was 
affected by the presence of A20FMDV2, despite their lack of the integrin receptor. This t-L/L 
ratio was lower than that of αvβ6 positive cell lines, however, and only occurred sporadically. 
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Figure 2: Cellular uptake of fluorescent liposomes in αvβ6 positive cancer cell lines in vitro. 
A375Pβ6 and PANC0403 cells were incubated with L or t-L labelled with 1mol% CF-DOPE for 
either 1 or 4 h. Cells were pre-treated on ice with either normal media (black bars) or media 
containing 50 μg/ml (grey bars) of the free A20FMDV2 peptide for 10 min prior to addition of the 
liposomes. Cellular uptake was assessed by measuring the mean fluorescence intensity (MFI) using 
flow cytometry (A) Flow cytometry plots demonstrate the reduction in t-L uptake in A375Pβ6 cells in 
the presence of free A20FMDV2. (B) A375Pβ6 showed reduced uptake of t-L when incubated with 
free A20FMDV2 at both 1 and 4 h. (C) Similarly, PANC0403 cells also showed a reduction in 
targeting ability of t-L when incubated with free A20FMDV2. *P < 0.05, **P < 0.01 (Student’s t test 
+A20FMDV2 vs. –A20FMDV2). 
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t-L-ALD are more effective than L-ALD at sensitising an integrin positive cell line to 
destruction by γδ T cells 
In order to test the therapeutic benefit of using liposomes targeted with the A20FMDV2 
peptide, ALD was encapsulated into L and t-L formulations. The ability of the resulting L-
ALD and t-L-ALD to sensitise cancer cell lines to destruction by Vγ9Vδ2 T cells was then 
tested by assessing cell viability and γδ T cell-derived IFN- γ production. The αvβ6 positive 
cell line A375Pβ6 was used in this assay. As shown in Figure 3, none of the treatments in 
isolation caused toxicity. However, when the cells were pre-treated with free or liposomal 
ALD, and were subsequently treated with γδ T cells, a significant decrease in cell viability 
was observed. t-L-ALD in combination with γδ T cells led to significantly lower cell viability 
than L-ALD at both 30 µM (p < 0.001) and 60 µM (p < 0.01) concentrations. To further 
confirm the increased sensitivity of αvβ6 positive cancer cells to γδ T cells when treated with 
t-L-ALD as compared to L-ALD, the IFN-γ release from the γδ T cells was quantified. 
Significantly higher amounts of IFN- γ were released when the γδ T cells were co-cultured 
with cells pre-treated with t-L-ALD as compared to L-ALD (p < 0.001 and p < 0.001 for 30 
µM and 60 µM, respectively). This finding is in agreement with the results obtained by the 
MTT assay. In the case of the αvβ6 negative cell line, A375Ppuro, no difference in the ability 
of L-ALD and t-L-ALD to sensitise the cells to γδ T cells was seen in terms of either 
cytotoxicity or IFN- γ release (Figure S6). 
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Figure 3: The ability of L-ALD and t-L-ALD to activate Vγ9Vδ2 T cells. (A) Cells were treated 
with ALD, L-ALD or t-L-ALD for 24 hours at 30 or 60 µM for 24 h. The treatments were then 
removed and replaced with 2 x 10
5
 γδ T cells for a further 24 h before a MTT assay was performed. t-
L-ALD increased the sensitivity of A375Pβ6 cells to γδ T cells compared to L-ALD (grey bars). 
ALD, L-ALD or t-L-ALD did not cause cytotoxicity alone at the concentrations used (black bars).  
(B) IFN-γ ELISA was performed on supernatant removed prior to the MTT assay. t-L-ALD led to 
higher release of IFN-γ from γδ T cells than L-ALD. Data was expressed as means ± SD (n=5). *p < 
0.05, (Student’s t test L-ALD vs. t-L-ALD). 
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Whole body SPECT/CT imaging of mice injected with 111In labelled L and t-L 
L and t-L were formulated with 1 % mol DSPE-DTPA and radiolabelled with 111In. Labelling 
efficiencies of 86.3 % and 61.9 % were obtained for L and t-L, respectively (Figure S7). 
Stability studies were performed after 24 hours at 37°C in both PBS and 50 % FBS in order 
to replicate in vivo conditions. For L, 87.8 % of the 111In remained bound to the liposomes 
after 24 hours incubation with PBS. On incubation of L with serum, 91% stability was seen. 
For t-L, 80.7 % and 78.2 % of 111In remained bound after 24 hours incubation with PBS and 
FBS, respectively.  
 
Tumour-bearing SCID/Beige mice were imaged by SPECT with computed tomography (CT) 
scanning to study the organ bio-distribution of radiolabelled L and t-L. The mice were 
inoculated with either the two melanoma or the two pancreatic human xenograft models on 
their back left flank (αvβ6 negative tumour: A375Ppuro or PANC-1) (right of the image) or 
right flank (αvβ6 positive tumour: A375Pβ6 or PANC0403) (left of the image). They were 
imaged immediately after injection, and 4 and 24 hours post-injection by SPECT/CT. As 
shown in Figure 4, no differences in the whole body bio-distribution for [111In]L and [111In]t-
L were observed. At early time-points, good blood circulation was observed for both types of 
liposomes as indicated by signals seen in the heart and head of the mice. Over time, the 
liposomes accumulated in the liver and spleen. Slight accumulation of the liposomes in the 
tumours could also be seen at later time-points, but this could not be clearly observed in these 
images, possibly due to masking by prolonged blood circulation of the liposomes. L and t-L 
gave comparable signals in both the positive and negative tumours. Gamma counting was 
used to quantify the tumour uptake of L and t-L. 
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Figure 4: In vivo whole body 3D SPECT/CT imaging of 
11
In labelled liposomes in tumour-
bearing immunocompromised mice . Mice were i.v injected with 
111
In labelled liposomes at a dose 
of 2 μmol lipid/mouse. Mice were inoculated bi-focally with the αvβ6 positive tumour on the left of 
the image (A375Pβ6) (right flank) and the negative tumour (A375Ppuro) on the right of the image 
(left flank). Whole body 3D SPECT/CT imaging were performed at 0-30min, 4 and 24 h post-
injection with scanning time of 40-60 min each. SPECT data is displayed in colour scale and CT data 
is in grey scale, respectively (high to low signals: top to bottom). 
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Comparable tumour distribution for both L and t-L was obtained in integrin negative 
and positive models.  
The organ bio-distribution and tumour uptake of [111In]L and [111In]t-L in tumour-bearing 
SCID/Beige mice, was then quantitatively determined by gamma counting. No significant 
differences were observed in the blood circulation profiles of [111In]L and [111In]t-L (Figure 
5A). At 1 h post administration, ~66 %ID of both formulations remained in the blood, 
decreasing to 31-39 %ID and ~8 %ID after 4 and 24 hours, respectively. L and t-L also had 
similar excretion profiles (Figure 5B), with only small fraction of the liposomes excreted 
within 24 hours in the urine (1.0 – 1.5 %ID) and faeces (0.30 – 0.37 %ID). In agreement with 
the SPECT imaging studies, liposomes accumulated mainly in the liver (L: 43 ± 3 %ID/g t-L: 
29 ± 9 %ID/g) and the spleen (L: 255.5 ± 89.7 %ID/g t-L: 219.4 ± 78.8 %ID/g) (Figure 5C 
and S8). No significant differences in the organ bio-distribution of [111In]L and [111In]t-L 
were observed. Additionally, no difference in uptake of t-L and L was observed in the αvβ6 
positive tumours. A comparison of the uptake of both [111In]L and [111In]t-L among the 
different tumour models showed that when the tumours were normalised by weight, there was 
no significant difference in the uptake of the liposomes among different tumour models (1.7 – 
3.2 %ID/g tumour). Once again no difference in bio-distribution was observed between 
[111In]L and [111In]t-L.  
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Figure 5: In vivo Bio-distribution of radiolabelled L and t-L in tumour bearing SCID/Beige mice 
after single dose administration via tail vein injection. (A) Blood clearance profile of liposomes 
expressed as %ID. (B) Excretion profile of liposomes after 24 hours expressed as %ID. (C) Results 
were expressed as percentage injected dose per gram of organ (%ID/g organ) at 24 h after injection of 
2 μmol liposome/mouse. Organ biodistribution data were taken from mice bearing A375Ppuro and 
A375Pβ6 tumours. No significant difference between the bio-distribution of the untargeted and 
targeted liposomes was seen. Data was expressed as means ± SD (n=3). 
 
 
Both L-ALD and t-L-ALD sensitise tumours to γδ T cell therapy in vivo 
L-ALD and t-L-ALD were used as a monotherapy and in combination with ex vivo-expanded 
Vγ9Vδ2 T cells in an experimental metastatic lung model with the αvβ6 positive A375Pβ6 
melanoma cell line in NOD-SCID gamma (NSG) mice. On day 6, all six groups had the same 
average tumour size (~1.3 x 106 photons, as determined by bioluminescence imaging). L-
ALD, t-L-ALD or γδ T cells as monotherapies did not result in a significant reduction in 
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tumour growth. Monotherapy with t-L-ALD showed a trend towards greater effectiveness 
than L-ALD (4.70 x 108 ± 1.78 x 108 vs. 1.24 x 109 ± 4.65 x 108 photons, day 27, p = 0.15). 
However, this difference was not significant due to variability in tumour size. Mice pre-
treated with L-ALD or t-L-ALD 24 h prior to injection of γδ T cells showed a significant 
reduction in tumour growth, with tumour sizes of 7.53 x 107 ± 2.02 x 107 and 9.06 x 107 ± 
3.33 x 107 photons, respectively, compared to 1.42 x 109 ± 6.38 x 108  photons for naïve 
tumours on day 27 (Figure 6). No improvement on the ability of t-L-ALD to sensitise the 
tumours to γδ T cells compared to L-ALD was observed. IFN-γ serum levels were measured 
on day 27.  Mice pre-treated with L-ALD or t-L-ALD prior to γδ T cells had levels of 32.6 ± 
19.3 and 12.3 ± 4.4 pg/ml (p < 0.05), respectively, compared to only 6.5 ± 0.9 pg/ml in γδ T 
cells-only treated group, mirroring the significant reduction in tumour growth observed in 
these groups.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: In vivo tumour therapy study. Experimental metastatic lung A375Pβ6 tumour bearing 
mice were treated intravenously on day 6 with L-ALD, t-L-ALD (0.5 µmol ALD/mouse), 1 x 10
7
 γδ T 
cells/mouse or were pre-treated with L-ALD or t-L-ALD 24 h prior to injection of γδ T cells. Three 
similar treatments were given intravenously at one week intervals, commencing on day 6 post-tumour 
inoculation. Tumour progression was monitored by bioluminescence imaging. A significant reduction 
in tumour growth was observed for the L-ALD/ and t-L-ALD/ combinatory immunotherapy 
groups compared to control mice or those treated with monotherapy of γδ T cells, L-ALD or t-L-
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ALD. t-L-ALD monotherapy resulted in an inhibition of tumour growth but this was not significant (p 
= 0.15). Data was expressed as mean ± SEM (n=7). *p < 0.05, (ANOVA). 
 
Use of mouse sera in cell uptake studies reduces receptor-mediated cell uptake of t-L in 
vitro 
In order to explore one possible explanation for the lack of improvement in therapeutic 
efficacy of t-L-ALD compared to L-ALD when used in combination with γδ T cells in 
therapy studies, cell uptake studies were performed in vitro, whereby t-L were pre-incubated 
with mouse serum and excess serum and unbound proteins were removed by size exclusion 
chromatography, prior to their 1h incubation with cell lines (Figure 7). Interestingly, this 
study showed the reduction in receptor-mediated uptake was indeed dependent on the 
incubation times with mouse serum.  This result suggests that mouse serum played a direct 
role in reducing active targeting efficiency in vivo. Unfortunately, whether this was a direct 
effect of the enzymes present in the serum on A20FMDV2 peptide’s stability or a protein 
corona effect, could not be precisely established. 
  
Figure 7: Effect of incubation of t-L with mouse serum on targeting efficacy. t-L were exposed to 
mouse serum for various lengths of times (10 min, 1 h, 4 h). The melanoma cell lines, A375Ppuro and 
A375Pβ6 were incubated with these liposomes for 1 h. Results are displayed as the MFI fold increase 
of naïve cells. Incubation of t-L with mouse serum leads to a reduction in receptor-mediated uptake 
cell uptake in the αvβ6 positive A375Pβ6 cell line. Cellular uptake was assessed by measuring the 
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MFI using flow cytometry and FL-1 detector. Values are expressed as mean ± SD (n= 3). *p < 0.05, 
**p < 0.01, (Student’s t test A375Ppuro vs. A375Pβ6). 
 
DISCUSSION 
In our study, αvβ6 positive cells were successfully targeted in vitro. Higher uptake of t-L 
versus L was observed in the A375Pβ6 and PANC0403 αvβ6 positive cell lines. This increased 
uptake of t-L led to an increased therapeutic efficacy of t-L-ALD at sensitising A375Pβ6 to γδ 
T cells when compared to L-ALD. The amount of receptor present on the surface of cells is a 
key consideration when evaluating a targeted drug delivery system. The expression of αvβ6 
receptor on A375Pβ6 cells was confirmed in vivo in a flank mouse tumour model in a previous study 
carried out by co-authors of this paper. SPECT/CT imaging showed that the radiolabelled peptide 
A20FMDV2 had seven times higher retention in the αvβ6 positive A375Pβ6 solid tumours than the 
αvβ6 negative A375Ppuro tumour implanted in the same mouse (Saha et al., 2010). This 
demonstrates the expression of the αvβ6 receptor in vivo. In our study, it has been shown that 
the targeting efficiency of t-L was linked to αvβ6 integrin receptor expression on the cell 
surface. As expected, the targeting efficiency was directly proportional the level of receptor 
expression, when comparing the three αvβ6 positive cell lines with A375Pβ6 > PANC0403 > 
4T1 in terms of both αvβ6 integrin receptor expression and targeting efficiency. This 
correlation has been previously reported by Elias et al. [33], with the density of the cell-
surface HER2/neu receptor shown to be an important factor in the targeting capability of 
HER2-targeted nanoparticles.  
 
While the peptide A20FMDV2 has previously been shown to selectively target the integrin 
receptor αvβ6 in vivo [12, 13, 34], it has not been conjugated to a nanoparticle before. In this 
work we provide evidence of successful conjugation of the peptide A20FMDV2 to the 
surface of liposomes for the first time, and have shown using in vitro peptide inhibition 
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studies that the t-L are taken up by cells in a receptor-specific manner. Only one study by 
Gray et al has specifically targeted the αvβ6 integrin receptor using a liposomal formulation 
[14]. In this study, liposomes were conjugated to the αvβ6-specific peptide, H2009.1. 
Interestingly, authors have shown that in vitro targeting using the αvβ6-positive cell line, 
H2009, could be achieved only when the peptide was incorporated in the tetrameric form and 
not the monomeric form. Our results have shown that in vitro targeting could be achieved 
despite using the monomeric form of the peptide. Future work investigating the use of 
multivalent forms of the peptide A20FMDV2 to further increase targeting efficiency is 
therefore worth investigating. 
 
In our study, while active targeting could be achieved in vitro using t-L, no increase in %ID/g 
tumour, could be seen in αvβ6 positive tumours during in vivo bio-distribution analysis. 
There have been previous reports in the literature demonstrating that peptide-targeted 
liposomes showed no improvement in tumour accumulation compared to untargeted 
liposomes in vivo [35]. It was therefore not surprising to see comparable tumour uptake data 
in vivo for L and t-L in all tumours tested. However, we hypothesised that targeting L-ALD 
to the αvβ6 integrin receptor, known to be overexpressed on cancer cells and absent on 
healthy cells, will result in increased uptake of t-L-ALD due to receptor-mediated 
endocytosis in vivo and hence better therapeutic outcomes, when combined with γδ T cell-
based immunotherapy. Kirpotin et al. demonstrated that despite no increase in tumour uptake 
of HER2 targeted liposomes in subcutaneous HER-2 positive breast cancer tumours in vivo, 
when excised tumours were studied using flow cytometry and microscopy, a 6-fold increase 
in cell internalisation of these targeted liposomes was observed [36]. Similarly, in another 
study, transferrin-targeted siRNA nanoparticles did not show an increase in tumour 
accumulation but resulted in a ~50 % decrease in tumour growth compared to non-targeted 
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nanoparticles due to increased cellular uptake [37]. Our therapy in experimental metastatic 
melanoma A375Pβ6-lung model results showed no added advantage using t-L-ALD over L-
ALD when used in combination with γδ T cells, following our treatment protocols. There 
could be several explanations to the results obtained; the most obvious one is that L-ALD, in 
combination with immunotherapy, resulted in efficient tumour growth delay, decreasing the 
scope for any further improvements, using the targeted delivery approach to be detected. 
Using lower doses of L-ALD and t-L-ALD may reveal a difference in therapeutic efficacy of 
the two formulations. Additionally, when L-ALD and t-L-ALD were used as monotherapies, 
mice treated with t-L-ALD had an average tumour size that was 2.6 times lower than that of 
mice treated with L-ALD. We hypothesise that this may be as results of higher affinity of  t-
L-ALD than L-ALD to A375Pβ6 cells as demonstrated during in vitro studies. Another 
possibility could be that ALD experiences better endosomal escape from t-L-ALD than L-
ALD, facilitated by the receptor-mediated uptake of the former. Unfortunately however, large 
variations in tumour size meant that this reduction in tumour size was not significant. Using 
higher doses of L-ALD and t-L-ALD as monotherapies or increasing the number of mice per 
treatment group may allow the difference in therapeutic efficacy to be observed.  
 
The lack of correlation between the in vitro and in vivo targeting efficacy that we observed 
agrees with a previous study by Gray et al [14]. As discussed above, liposomes targeted using 
the αvβ6-specific peptide H2009 in its tetrameric form demonstrated encouraging findings in 
vitro, with a 5-10 fold increase in uptake for targeted liposome. However, targeted liposomes 
did not lead to an improvement in targeting or efficacy in vivo using an αvβ6 positive H2009 
subcutaneous tumour model [35]. Gray and his colleagues, concluded that it is the properties 
of the liposome (size and PEGylation) and not the targeting peptide that determines in vivo 
bio-distribution. Poor tumour penetration due to the dense extracellular matrix and high 
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interstitial pressure in solid tumours may have prevented liposomes from exerting a targeting 
effect within the tumour itself [38, 39]. Likewise, a folate-targeted formulation of L-ALD 
demonstrated in vitro targeting but no therapeutic advantage was observed during in vivo 
studies with a folate receptor-α positive ovarian tumour model [24]. The presence of folate 
receptors on endogenous non-tumour cells leading to accelerated systemic clearance was 
hypothesised to be responsible for the lower therapeutic efficacy of the targeted formulation.  
 
Recent studies have revealed that the formation of a protein corona on the surface of 
liposomes can lead to an inhibition of targeting efficacy, as the targeting-peptides can be 
hidden from their receptors [40-43]. We have therefore conducted a study to see if incubation 
of t-L-ALD with mouse serum will compromise the targeting efficiency, in an attempt to 
correlate the in vitro targeting efficiency with in vivo active targeting in a living mouse.  Our 
results indeed showed that incubation with mouse serum reduced the targeting efficiency of t-
L, in a time-dependent manner.  This suggests that the direct interaction of mouse serum and 
t-L adversely affects active targeting of t-L-ALD. Further studies to explore types of protein 
corona involved are warranted and as it has been reported that protein corona may differ 
based on what species the serum is from, extrapolation of data in mice to humans is not 
possible [40].  Another explanation of the mouse serum data could be the enzymatic 
degradation of A20FMDV2. A study performed by Saha et al. has shown that only 50% of 
the peptide A20FMDV2 [13] remained intact after 4 h incubation with mouse serum. Amino 
acid modifications may help improve resistance to enzymatic degradation [44-46]. To 
understand the exact effect of serum on active targeting in our study needs further 
investigation.  
 
CONCLUSION 
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In this work, A20FMDV2 peptide was successfully conjugated to PEGylated liposomes and 
active targeting was confirmed in vitro in melanoma and pancreatic cells lines.  In vitro 
targeting efficiency was directly linked to levels of αvβ6 receptor expressions and was 
blocked by addition of excess peptide, suggesting receptor-mediated endocytosis as a 
mechanism of internalisation. αvβ6-targeted liposomal alendronate led to significant 
improvement in sensitisation of αvβ6 positive cancer cell line to γδ T cells, and improved cell 
kill in vitro. Despite the slight promise in using t-L-ALD as a monotherapy, no added 
advantage was observed when combined with γδ T cells immunotherapy, in an experimental 
metastatic lung mice model. Future therapy studies with modified treatment protocols need to 
be performed to determine if a significant improvement in therapeutic efficacy using t-L-
ALD can be achieved. In vivo peptide stability and the protein corona effect may be 
responsible for the decrease in in vivo targeting efficacy compared to the in vitro results 
obtained, which also needs to be investigated further. 
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Figure 1: The effect of the extent of expression of αvβ6 integrin receptor on the uptake 
of t-L. (A) Representative images of cell lines incubated with the antibody 10D5 (specific to 
αvβ6) or an isotype control. Cells were analysed for αvβ6 integrin receptor expression using 
flow cytometry and FL-1 detector. In a comparison of the αvβ6 expression of different cell 
lines using the % positive cells gated in M1 or the MFI, the 4T1 cancer cell line showed the 
lowest receptor expression, while A375Pβ6 has the highest expression both in terms of % of 
positive cells and the number of receptors per cell. (B) Comparison of the MFI fold increase 
of fluorescently labelled t-L to L. Cells were treated with 32.5 µM L or t-L for 1 or 4 h. With 
increasing expression of αvβ6, the uptake of t-L in relation to L further increases. This is a 
further indication of the specificity of the t-L to the αvβ6 integrin receptor. Values are 
expressed as mean ± SD (n= 3). *P < 0.05, **P < 0.01, ***P < 0.001 (Student’s t test vs. 
each cell line).  
 
Figure 2: Cellular uptake of fluorescent liposomes in αvβ6 positive cancer cell lines in 
vitro. A375Pβ6 and PANC0403 cells were incubated with L or t-L labelled with 1mol% CF-
DOPE for either 1 or 4 h. Cells were pre-treated on ice with either normal media (black bars) 
or media containing 50 μg/ml (grey bars) of the free A20FMDV2 peptide for 10 min prior to 
addition of the liposomes. Cellular uptake was assessed by measuring the mean fluorescence 
intensity (MFI) using flow cytometry (A) Flow cytometry plots demonstrate the reduction in 
t-L uptake in A375Pβ6 cells in the presence of free A20FMDV2. (B) A375Pβ6 showed 
reduced uptake of t-L when incubated with free A20FMDV2 at both 1 and 4 h. (C) Similarly, 
PANC0403 cells also showed a reduction in targeting ability of t-L when incubated with free 
A20FMDV2. *P < 0.05, **P < 0.01, ***P < 0.001 (Student’s t test +A20FMDV2 vs. –
A20FMDV2). 
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Figure 3: The ability of L-ALD and t-L-ALD to activate Vγ9Vδ2 T cells. (A) Cells were 
treated with ALD, L-ALD or t-L-ALD for 24 hours at 30 or 60 µM for 24 h. The treatments 
were then removed and replaced with 2 x 10
5
 γδ T cells for a further 24 h before a MTT assay 
was performed. t-L-ALD increased the sensitivity of A375Pβ6 cells to γδ T cells compared to 
L-ALD (grey bars). ALD, L-ALD or t-L-ALD did not cause cytotoxicity alone at the 
concentrations used (black bars).  (B) IFN-γ ELISA was performed on supernatant removed 
prior to the MTT assay. t-L-ALD led to higher release of IFN-γ from γδ T cells than L-ALD. 
Data was expressed as means ± SD (n=5). *p < 0.05, (Student’s t test L-ALD vs. t-L-ALD). 
 
Figure 4: In vivo whole body 3D SPECT/CT imaging of 
11
In labelled liposomes in 
tumour-bearing immunocompromised mice. Mice were i.v injected with 
111
In labelled 
liposomes at a dose of 2 μmol lipid/mouse. Mice were inoculated bi-focally with the αvβ6 
positive tumour on the left of the image (A375Pβ6) (right flank) and the negative tumour 
(A375Ppuro) on the right of the image (left flank). Whole body 3D SPECT/CT imaging were 
performed at 0-30min, 4 and 24 h post-injection with scanning time of 40-60 min each.  
 
 
Figure 5: In vivo Bio-distribution of radiolabelled L and t-L in tumour bearing 
SCID/Beige mice after single dose administration via tail vein injection. (A) Blood 
clearance profile of liposomes expressed as %ID. (B) Excretion profile of liposomes after 24 
hours expressed as %ID. (C) Results were expressed as percentage injected dose per gram of 
organ (%ID/g organ) at 24 h after injection of 2 μmol liposome/mouse. No significant 
difference between the bio-distribution of the untargeted and targeted liposomes was seen. 
Data was expressed as means ± SD (n=3). 
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Figure 6: In vivo tumour therapy study. Experimental metastatic lung A375Pβ6 tumour 
bearing mice were treated intravenously on day 6 with L-ALD, t-L-ALD (0.5 µmol 
ALD/mouse), 1 x 10
7
 γδ T cells/mouse or were pre-treated with L-ALD or t-L-ALD 24 h 
prior to injection of γδ T cells. Three similar treatments were given intravenously at one week 
intervals, commencing on day 6 post-tumour inoculation. Tumour progression was monitored 
by bioluminescence imaging. A significant reduction in tumour growth was observed for the 
L-ALD/ and t-L-ALD/ combinatory immunotherapy groups compared to control mice or 
those treated with monotherapy of γδ T cells, L-ALD or t-L-ALD. t-L-ALD monotherapy 
resulted in an inhibition of tumour growth but this was not significant (p = 0.15). Data was 
expressed as mean ± SEM (n=7). *p < 0.05, (Student’s t test vs. naïve). 
 
 
Figure 7: Effect of incubation of t-L with mouse serum on targeting efficacy. t-L were 
exposed to mouse serum for various lengths of times (10 min, 1 h, 4 h). The melanoma cell 
lines, A375Ppuro and A375Pβ6 were incubated with these liposomes for 1 h. Results are 
displayed as the MFI fold increase of naïve cells. Incubation of t-L with mouse serum leads to 
a reduction in receptor-mediated uptake cell uptake in the αvβ6 positive A375Pβ6 cell line. 
Cellular uptake was assessed by measuring the MFI using flow cytometry and FL-1 detector. 
Values are expressed as mean ± SD (n= 3). *p < 0.05, **p < 0.01, ***p < 0.001, (Student’s t 
test A375Ppuro vs. A375Pβ6). 
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TO C: Formulation of αvβ6 targeted liposomes. Liposomes were formulated with 1 % DSPE-PEG2000 Maleimide (%mol/total lipid).  
The peptide  A20FMDV2 was modified to contain a cysteine residue at the C-terminus. These liposomes were incubated with 25 µg peptide/ 
µmol lipid of the peptide A20FMDV2 overnight at RT. The thiol group of the C-terminus cysteine residue reacts with the maleimide group 
 to form a thioether bond.
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